A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1
William H. Bradley,Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byoung-Gie Kim,Ana Oaknin,Michael Friedlander,Alla Lisyanskaya,Anne Floquet,Alexandra Leary,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martín,Carol Aghajanian,Theresa Cain,Elizabeth S. Lowe,Paul DiSilvestro +18 more
TL;DR: For pts with a BRCAm and newly diagnosed advanced ovarian cancer, the benefit derived from 2 years of maintenance olaparib was sustained beyond the end of treatment, and after 5 years, almost half of pts were progression free vs 20% with placebo, consistent across higher- and lower-risk pts.
Journal ArticleDOI
The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.
Bradley J. Monk,Rachel N. Grisham,Christian Marth,Susana Banerjee,Felix Hilpert,Robert L. Coleman,Eric Pujade-Lauraine,Sandro Pignata,Mansoor Raza Mirza,Amit M. Oza,Josep M. del Campo,Martin K. Oehler,Adam James,Janna Christy-Bittel,Emma Barrett,Adam P. Boyd,Ignace Vergote +16 more
TL;DR: Low grade serous (LGS) carcinomas of the ovary, fallopian tube and primary peritoneum are a unique subset of serous carcinomas for which current therapies (chemotherapy, hormona, etc.) are ineffective.
Journal ArticleDOI
Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
Katarzyna J. Jerzak,Shaidah Deghan Manshadi,Pamela Ng,Manjula Maganti,Jeanna McCuaig,Marcus Bulter,Amit M. Oza,Helen Mackay +7 more
TL;DR: The administration of diphenhydramine to women who have a platinum-free interval may reduce the risk of hypersensitivity reaction, but prospective evaluation is required.
Journal ArticleDOI
A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors
Amit M. Oza,François Dubois,Roberto Hegg,Carlos Alberto Hernández,G. Finocchiaro,François Ghiringhelli,Claudio Zamagni,Sonja Nick,Natsumi Irahara,Thomas Perretti,Nicoletta Colombo +10 more
TL;DR: In this paper, the authors assessed the long-term safety and tolerability of bevacizumab among patients with solid tumors, with a median extended treatment duration of almost 5 years in some individual patients.
Journal ArticleDOI
The role of niraparib for the treatment of ovarian cancer.
TL;DR: The role of niraparib in the treatment of EOC is focused on, leading to the first polyadenosine diphosphate-ribose polymerase inhibitors approval by the US FDA in this setting.